Ovarian cancers carrying BRCA1 and BRCA2 mutations (mBRCA) display massive chromosomal alterations [4,5], and are more sensitive to DNA cross-linking agents containing platinum, and to PARP inhibitors [6,7]. This evidence concerns the gene BRCA1 and ovarian cancer.